Myelofibrosis
📧 Sign up to get email alerts when something new happens for Myelofibrosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-11Clinical Trial Results: Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis [Phase 3]
Phase III study of SAR302503 in intermediate-2 and high-risk myelofibrosis was terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2026-08-04Clinical Trial Results: Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis [Phase 1, Phase 2]
Phase 1/2 trial evaluating safety, PK/PD, and dose escalation/expansion of PXS-5505 in patients with myelofibrosis (including PMF and post-P…
-
CLINICAL_TRIALS trial_result · 2026-07-16Clinical Trial Results: Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib [Phase 2]
Phase II open-label single-arm trial of SAR302503 in myelofibrosis patients previously treated with ruxolitinib.
-
CLINICAL_TRIALS trial_result · 2026-07-09Clinical Trial Results: Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. [Phase 2]
Phase 2 trial evaluating ruxolitinib before, during, and after hematopoietic stem cell transplantation in patients with primary or secondary…
-
CLINICAL_TRIALS trial_result · 2026-06-04Clinical Trial Results: A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating CPI-0610 with and without ruxolitinib in hematologic and myeloproliferative malignancies; study complete…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms [Phase 1, Phase 2]
The Phase 1/2 study evaluating the combination of ruxolitinib and CPX-351 in advanced phase myeloproliferative neoplasms was terminated, wit…
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis [Phase 2, Phase 3]
A clinical trial update notes that luspatercept is being evaluated in Phase 2/Phase 3 studies to prevent poor erythroid engraftment in patie…
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: Extended Access of Momelotinib in Adults With Myelofibrosis [Phase 2]
This clinical trial update notes extended-access use of momelotinib in adults with myelofibrosis, including primary myelofibrosis and relate…
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis) [Phase 1]
The update reports on tolerability of adding Ropeginterferon alfa-2b to ongoing ruxolitinib therapy in patients with myelofibrosis in a Phas…
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies [Phase 2]
Phase 2 study evaluating a two-step reduced-intensity conditioning approach for bone marrow transplant in adults with hematologic malignanci…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis [Phase 2]
Phase 2 clinical trial update on peritransplant ruxolitinib for patients with primary or secondary myelofibrosis, currently active but not r…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis [Phase 2]
A Phase 2 clinical study is evaluating the combination of ruxolitinib and thalidomide for patients with myelofibrosis; the trial status is a…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Fedratinib in Combination With Nivolumab [Phase 2]
This Phase 2 trial evaluates the combination of fedratinib and nivolumab in patients with Primary myelofibrosis or Secondary myelofibrosis a…
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms [Phase 1]
An update on a Phase 1 safety and tolerability study of INCB057643 in myelofibrosis and other advanced myeloid neoplasms, with the trial cur…
-
CLINICAL_TRIALS trial_result · 2026-03-31Clinical Trial Update: Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm [Phase 2]
This Phase 2 trial update reports completion of a study evaluating the combination of ruxolitinib phosphate and azacitidine in patients with…
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms [Phase 2]
Phase 2 clinical trial evaluating curcumin to improve inflammation and symptoms in patients with clonal cytopenia of undetermined significan…
-
CLINICAL_TRIALS trial_result · 2026-03-25Clinical Trial Update: TP-3654 Food Effect Study [Phase 1]
Phase 1 food-effect study of TP-3654 in myelofibrosis has completed.
-
CLINICAL_TRIALS trial_result · 2026-03-23Clinical Trial Update: Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis [Phase 3]
A Phase 3 trial evaluating navitoclax in combination with ruxolitinib versus ruxolitinib alone in adults with myelofibrosis has completed an…
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: CINC424A2X01B Rollover Protocol [Phase 4]
Phase 4 rollover protocol for CINC424A2X01B is active but not recruiting, spanning Primary Myelofibrosis, Polycythemia Vera, Graft-versus-ho…
-
CLINICAL_TRIALS trial_result · 2026-03-04Clinical Trial Update: A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis [Phase 3]
This is a Phase 3 clinical trial evaluating Flonoltinib Maleate for intermediate- or high-risk myelofibrosis. The trial is currently recruit…
-
CLINICAL_TRIALS trial_result · 2026-02-06Clinical Trial Update: Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia [Phase 2]
A Phase 2 trial update evaluating pacritinib for bone marrow fibrosis in patients with myelofibrosis who have thrombocytopenia; the study is…
-
CLINICAL_TRIALS trial_result · 2026-01-12Clinical Trial Update: Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis [Phase 2]
Phase 2 clinical trial evaluating reduced intensity haploidentical transplantation for primary or secondary myelofibrosis is currently recru…
-
CLINICAL_TRIALS trial_result · 2026-01-06Clinical Trial Update: Role of Myeloid-derived Suppressor Cells In Primary Myelofibrosis
The study investigates the role of myeloid-derived suppressor cells in primary myelofibrosis, and the trial has completed.
-
CLINICAL_TRIALS trial_result · 2026-01-05Clinical Trial Update: A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT [Phase 1]
Phase 1 trial evaluating a combination of CD25/Treg-depleted donor lymphocyte infusion with ipilimumab for relapse of myeloid diseases after…
-
CLINICAL_TRIALS trial_result · 2025-12-23Clinical Trial Update: INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders [Phase 1, Phase 2]
Clinical trial update shows INCB000928 is being studied as a monotherapy or in combination with ruxolitinib for anemia due to myeloprolifera…